➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DORIPENEM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Doripenem

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00210938 Doripenem in the Treatment of Complicated Intra-Abdominal Infections Completed Peninsula Pharmaceuticals, Inc. Phase 3 2004-03-01 The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
NCT00210938 Doripenem in the Treatment of Complicated Intra-Abdominal Infections Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-03-01 The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.
NCT00210990 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed Peninsula Pharmaceuticals, Inc. Phase 3 2004-03-01 The purpose of this study is to assess the microbiological cure rate of doripenem in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.
NCT00210990 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-03-01 The purpose of this study is to assess the microbiological cure rate of doripenem in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.
NCT00211003 Doripenem in the Treatment of Hospital-Acquired Pneumonia Completed Peninsula Pharmaceuticals, Inc. Phase 3 2004-05-01 The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).
NCT00211003 Doripenem in the Treatment of Hospital-Acquired Pneumonia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2004-05-01 The purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (HAP).
NCT00211016 Doripenem in the Treatment of Ventilator-Associated Pneumonia Completed Peninsula Pharmaceuticals, Inc. Phase 3 2004-08-01 The purpose of this study is to compare the clinical response rate of doripenem versus comparator in patients with ventilator-associated pneumonia (VAP).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Doripenem

Condition Name

Condition Name for Doripenem
Intervention Trials
Ventilator-Associated Pneumonia 5
Urinary Tract Infections 5
Pneumonia 5
Pneumonia, Ventilator-Associated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Doripenem
Intervention Trials
Infection 15
Communicable Diseases 13
Pneumonia 12
Pneumonia, Ventilator-Associated 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Doripenem

Trials by Country

Trials by Country for Doripenem
Location Trials
United States 67
Argentina 7
Ukraine 6
Canada 5
Brazil 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Doripenem
Location Trials
Ohio 7
Michigan 7
California 6
Arkansas 4
District of Columbia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Doripenem

Clinical Trial Phase

Clinical Trial Phase for Doripenem
Clinical Trial Phase Trials
Phase 4 8
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Doripenem
Clinical Trial Phase Trials
Completed 22
Terminated 5
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Doripenem

Sponsor Name

Sponsor Name for Doripenem
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 8
Peninsula Pharmaceuticals, Inc. 6
Janssen Research & Development, LLC 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Doripenem
Sponsor Trials
Industry 29
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Baxter
Johnson and Johnson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.